Membrane perturbing actions of HIV type 1 glycoprotein 41 domains are inhibited by helical C-peptides

AIDS Research and Human Retroviruses

Volumn 23, Issue 2, 2007, Pages 224-242

  Mobley, Patrick W ^a   Barry, Jay A ^a   Waring, Alan J ^b,c   Sherman, Mark A ^d   Gordon, Larry M ^c  

^a CALIFORNIA STATE POLYTECHNIC UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; ENFUVIRTIDE; GLYCOPROTEIN GP 41; HYBRID PROTEIN; LEUCINE ZIPPER PROTEIN; SYNTHETIC PEPTIDE; TRYPTOPHAN; VIRUS GLYCOPROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL AGGREGATION; CELL SURFACE; CONTROLLED STUDY; ERYTHROCYTE; HEMOLYSIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INFRARED SPECTROSCOPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; VIRUS ENVELOPE;

CIRCULAR DICHROISM; ERYTHROCYTE AGGREGATION; ERYTHROCYTE MEMBRANE; HEMOLYSIS; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; LEUCINE ZIPPERS; MEMBRANE FUSION; PEPTIDE FRAGMENTS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 33947254649     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.0046     Document Type: Article

References (99)

1. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, Alldredge L, Hunter E, Lambert D, Bolognesi D, Matthews T, Johnson MR, Nowak MA, Shaw GM, and Saag MS: Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998;4:1302-1307.
2. Chan DC and Kim PS: HIV entry and its inhibition. Cell 1998;93:681-684.
3. Jiang S, Zhao Q, and Debnath AK: Peptide and non-peptide HIV fusion inhibitors. Curr Pharm Des 2002;8:563-580.
4. Gallo SA, Finnegan CM, Viard M, Raviv Y, Dimitrov AS, Rawat SS, Puri A, Durell S, and Blumenthal R: The HIV Env-mediated fusion reaction. Biochim Biophys Acta 2003;1614:36-50.
5. Aloia RC, Jensen FC, Curtain CC, Mobley PW, and Gordon LM: Lipid composition and fluidity of the human immunodeficiency virus type-1. Proc Natl Acad Sci USA 1988;85:900-904.
6. Gordon LM, Jensen FC, Curtain CC, Mobley PW, and Aloia RC: Thermotropic lipid phase separation in the human immunodeficiency virus. Biochim Biophys Acta 1988;943:331-342.
7. + cells by simian immunodeficiency virus: Productive infection associated with envelope glycoprotein-induced fusion. Proc Natl Acad Sci USA 1989;86:2443-2447.
8. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, and Wiley DC: Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997;387:426-430.
9. Chan DC, Fass D, Berger M, and Kim PS: Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997;89:263-273.
10. Bullough PA, Hughson FM, Skehel JJ, and Wiley DC: Structure of influenza haemagglutinin at the pH of membrane fusion. Nature 1994;371:37-43.
11. Carr CM and Kim PS: A spring-loaded mechanism for the conformational change of influenza hemagglutinin. Cell 1993;73:823-832.
12. Lu M, Blacklow SC, and Kim PS: A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 1995;2:1075-1082.
13. Mobley PW, Waring AJ, Sherman MA, and Gordon LM: Membrane interactions of the synthetic N-terminal peptide of HIV-1 gp41 and its structural analogs. Biochim Biophys Acta 1999;1418:1-18.
14. 13C-enhanced Fourier transform infrared spectroscopy. Biochim Biophys Acta 2002;1559:96-120.
15. + lymphocytes. Biochim Biophys Acta 1992;1139:251-256.
16. Dimitrov AS, Xiao X, Dimitrov DS, and Blumenthal R: Early intermediates in HIV-1 envelope glycoprotein-mediated fusion triggered by CD4 and co-receptor complexes. J Biol Chem 2001;276:30335-30341.
17. Mobley PW, Pilpa R, Brown C, Waring AJ, and Gordon LM: Membrane-perturbing domains of HIV type 1 glycoprotein 41. AIDS Res Hum Retroviruses 2001;17:311-327.
18. Mobley PW, Lee H-F, Curtain CC, Kirkpatrick A, Waring AJ, and Gordon LM: The amino-terminal peptide of HIV-1 glycoprotein 41 fuses human erythrocytes. Biochim Biophys Acta 1995;1271:304-315.
19. Pereira FB, Goni FM, and Nieva JL: Liposome destabilization induced by the HIV-1 fusion peptide: Effect of a single amino acid substitution. FEBS Lett 1995;362:243-246.
20. Martin I, Schaal H, Scheid A, and Ruysschaert J-M: Lipid membrane fusion induced by the human immunodeficiency virus type 1 gp41 N-terminal extremity is determined by its orientation in the lipid bilayer. J Virol 1996;70:298-304.
21. Kliger Y, Aharoni A, Rapaport D, Jones P, Blumenthal R, and Shai Y: Fusion peptides derived from the HIV type 1 glycoprotein 41 associate within phospholipid membranes and inhibit cell-cell fusion. J Biol Chem 1997;272:13496-13505.
22. Pereira FB, Goni FM, and Nieva JL: Permeabilization and fusion of uncharged lipid vesicles induced by the HIV-1 fusion peptide adopting an extended conformation: Dose and sequence effects. Biophys J 1997;73:1977-1986.
23. Jiang S, Lin K, Strick N, and Neurath AR: Inhibition of HIV-1 infection by a fusion domain binding peptide from the HIV-1 envelope glycoprotein gp41. Biochem Biophys Res Commun 1993;195:533-538.
24. Neurath AR, Lin K, Strick N, and Jiang S: Two partially overlapping antiviral peptides from the external portion of HIV type 1 glycoprotein 41, adjoining the transmembrane region, affect the glycoprotein 41 fusion domain. AIDS Res Hum Retroviruses 1995;11:189-190.
25. Gordon LM, Waring AJ, Curtain CC, Kirkpatrick A, Leung C, Faull K, and Mobley PW: Antivirals that target the amino-terminal domain of HIV-1 gp41. AIDS Res Hum Retroviruses 1995;11:677-686.
26. Pereira FB, Goni FM, and Nieva JL: Membrane fusion induced by the HIV type 1 fusion peptide: Modulation by factors affecting glycoprotein 41 activity and potential anti-HIV compounds. AIDS Res Hum Retroviruses 1997;13:1203-1211.
27. Chang D-K, Cheng S-F, and Chien W-J: The amino-terminal fusion domain peptide of human immunodeficiency virus type 1 gp41 inserts into the sodium dodecyl sulfate micelle primarily as a helix with a conserved glycine at the micelle-water interface. J Virol 1997;71:6593-6602.
28. Morris KF, Gao X, and Wong TC: The interactions of HIV gp41 fusion peptides with zwitterionic membrane mimics determined by NMR spectroscopy. Biochim Biophys Acta 2004;1667:67-81.
29. 13C-enhanced Fourier transform infrared spectroscopy. Protein Sci 2004;13:1012-1030.
30. Yang J, Gabrys CM, and Weliky DP: Solid-state nuclear magnetic resonance evidence for an extended β strand conformation of the membrane-bound HIV-1 fusion peptide. Biochemistry 2001;40:8126-8137.
31. Kanyalkar M, Srivastava S, Saran A, and Coutinho E: Conformational study of fragments of envelope proteins (gp120: 254-274 and gp41: 519-541) of HIV-1 by NMR and MD simulations. J Peptide Sci 2004;10:363-380.
32. Dubay JW, Roberts SJ, Brody B, and Hunter E: Mutations in the leucine zipper of the human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and infectivity. J Virol 1992;66:4748-4756.
33. Cao J, Bergeron L, Helseth E, Thali M, Repke H, and Sodroski J: Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein. J Virol 1993;67:2747-2755.
34. Chen SSL: Functional role of the zipper motif region of human immunodeficiency virus type 1 transmembrane protein gp41. J Virol 1994;68:2002-2010.
35. Chen SSL, Lee C-N, Lee W-R, McIntosh K, and Lee T-H: Mutational analysis of the leucine zipper-like motif of the human immunodeficiency virus type 1 envelope transmembrane glycoprotein. J Virol 1993;67:3615-3619.
36. Wild C, Oas T, McDanal C, Bolognesi D, and Matthews T: A synthetic peptide inhibitor of human immunodeficiency virus replication: Correlation between solution structure and viral inhibition. Proc Natl Acad Sci USA 1992;89:10537-10541.
37. Kazmierski WM, Hazen RJ, Aulabaugh A, and StClair MH: Inhibitors of human immunodeficiency virus type 1 derived from gp41 transmembrane protein: Structure-activity studies. J Med Chem 1996;39:2681-2689.
38. Lawless MK, Barney S, Guthrie KI, Bucy TB, Petteway SR Jr, and Merutka G: HIV-1 membrane fusion mechanism: Structural studies of the interactions between biologically-active peptides from gp41. Biochemistry 1996;35:13697-13708.
39. Rabenstein M and Shin Y-K: A peptide from the heptad repeat of human immunodeficiency virus gp41 shows both membrane binding and coiled-coil formation. Biochemistry 1995;34:13390-13397.
40. Rabenstein MD and Shin Y-K: HIV-1 gp41 tertiary structure studied by EPR spectroscopy. Biochemistry 1996;35:13922-13928.
41. Wild C, Greenwell T, Shugars D, Rimsky-Clarke L, and Matthews T: The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure. AIDS Res Hum Retroviruses 1995;11:323-325.
42. Consonni R, Limiroli R, Longhi R, Manera E, Vecchio G, Ragona L, Siccardi AG, and Zetta L: NMR and CD studies on the conformation of a synthetic peptide containing epitopes of the human immunodeficiency virus 1 transmembrane protein gp41. Biopolymers 1996;38:423-435.
43. Chang D-K, Cheng S-F, Trivedi VD, and Lin K-L: Proline affects oligomerization of a coiled coil by inducing a kink in a long helix. J Struct Biol 1999;128:270-279.
44. Chang D-K, Cheng S-F, and Trivedi VD: Biophysical characterization of the structure of the amino-terminal region of gp41 of HIV-1. J Biol Chem 1999;274:5299-5309.
45. Sackett K and Shai Y: How structure correlates to function for membrane associated HIV-1 gp41 constructs corresponding to the N-terminal half of the ectodomain. J Mol Biol 2003;333:47-58.
46. Santos NC, Prieto M, and Castanho MARB: Interaction of the major epitope region of HIV protein gp41 with membrane model systems. A fluorescence spectroscopy study. Biochemistry 1998;37:8674-8682.
47. Salzwedel K, West JT, and Hunter E: A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for env-mediated fusion and virus infectivity. J Virol 1999;73:2469-2480.
48. Wild C, Greenwell T, and Matthews T: A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus mediated cell-cell fusion. AIDS Res Hum Retroviruses 1993;9:1051-1053.
49. Jiang S, Lin K, Strick N, and Neurath AR: HIV-1 inhibition by a peptide. Nature 1993;365:113.
50. Munoz-Barroso I, Durell S, Sakaguchi K, Apella E, and Blumenthal R: Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41. J Cell Biol 1998;140:315-323.
51. Saez-Cirion A, Nir S, Lorizate M, Agirre A, Cruz A, Perez-Gil J, and Nieva JL: Sphingomyelin and cholesterol promote HIV-1 gp41 pretransmembrane sequence surface aggregation and membrane restructuring. J Biol Chem 2002;277:21776-21785.
52. Heil ML, Decker JM, Sfakianos JN, Shaw GM, Hunter E, and Derdeyn CA: Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site. J Virol 2004;78:7582-7589.
53. Liu S, Lu H, Niu J, Xu Y, Wu S, and Jiang S: Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J Biol Chem 2005;280:11259-11273.
54. Perez-Alvarez L, Carmona R, Ocampo A, Asorey A, Miralles C, Perez de Castro S, Pinilla M, Contreras G, Taboada JA, and Najera R: Long-term monitoring of genotypic and phenotypic resistance to T20 in treated patients infected with HIV-1. J Med Virol 2006;78:141-147.
55. Joyce JG, Hurni WM, Bogusky MJ, Garsky VM, Liang X, Citron MP, Danzeisen RC, Miller MD, Shiver JW, and Keller PM: Enhancement of alpha-helicity in the HIV-1 inhibitory peptide DP-178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro: Implications for vaccine design. J Biol Chem 2002;277:45811-45820.
56. Biron Z, Khare S, Quadt SR, Hayek Y, Naider F, and Anglister J: The 2F5 epitope is helical in the HIV-1 entry inhibitor T-20. Biochemistry 2005;44:13611.
57. Kliger Y, Gallo SA, Peisajovich SG, Munoz-Barroso I, Avkin S, Blumenthal R, and Shai Y: Mode of action of an antiviral peptide from HIV-1: Inhibition at a post-lipid mixing stage. J Biol Chem 2001;276:1391-1397.
58. Suarez T, Nir S, Goni FM, Saez-Cirion A, and Nieva JL: The pre-transmembrane region of the human immunodeficiency virus type-1 glycoprotein: A novel fusogenic sequence. FEBS Lett 2000;477:145-149.
59. Suarez T, Gallaher WR, Agirre A, Goni FM, and Nieva JL: Membrane interface-interacting sequences within the ectodomain of the human immunodeficiency virus type 1 envelope glycoprotein: Putative role during viral fusion. J Virol 2000;74:8038-8047.
60. Saez-Cirion A, Arrondo JLR, Gomara MJ, Lorizate M, Iloro I, Melikyan G, and Nieva JL: Structural and functional roles of HIV-1 gp41 pretransmembrane sequence segmentation. Biophys J 2003;85:3780.
61. Shnaper S, Sackett K, Gallo SA, Blumenthal R, and Shai Y: The C- and N-terminal regions of glycoprotein 41 ectodomain fuse membranes enriched and not enriched with cholesterol, respectively. J Biol Chem 2004;279:18526-18534.
62. Moreno MR, Pascual R, and Villalain I: Identification of membrane-active regions of the HIV-1 envelope glycoprotein gp41 using a 15-mer gp41-peptide scan. Biochim Biophys Acta 2004;1661:97-105.
63. Schibli DJ, Montelaro RC, and Vogel HJ: The membrane-proximal tryptophan-rich region of the HIV glycoprotein, gp41, forms a well-defined helix in dodecylphosphocholine micelles. Biochemistry 2001;40:9570-9578.
64. Dimitrov AS, Rawat SS, Jiang S, and Blumenthal R: Role of the fusion peptide and membrane-proximal domain in HIV-1 envelope glycoprotein-mediated membrane fusion. Biochemistry 2003;42:14150-14158.
65. Myers G, Korber B, Berzofsky JA, Smith RF, and Pavalakis GN: Human Retroviruses and AIDS 1991: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences. Los Alamos National Laboratory, Los Alamos, NM, 1991, p. 11-81.
66. Gordon LM, Curtain CC, Zhong YC, Kirkpatrick A, Mobley PW, and Waring AJ: The amino terminal peptide of HIV-1 glycoprotein 41 interacts with human erythrocyte membranes: Peptide conformation, orientation and aggregation. Biochim Biophys Acta 1992;1139:257-274.
67. Gordon LM, Curtain CC, McCloyn V, Kirkpatrick A, Mobley PW, and Waring AJ: The amino-terminal peptide of HIV-1 gp41 interacts with human serum albumin. AIDS Res Hum Retroviruses 1993;9:1145-1156.
68. Johnson WCJ: Protein secondary structure and circular dichroism: A practical guide. Proteins Struct Funct Genet 1990;7:205-214.
69. Byler DM and Susi H: Examination of the secondary structure of protein by deconvolved FTIR spectra. Biopolymers 1986;25:469-487.
70. Eisenberg D and Wesson M: The most highly amphipathic alpha helices include two amino acid segments in human immunodeficiency virus glycoprotein gp41. Biopolymers 1990;29:171-177.
71. Woody RW: Contributions of tryptophan side chains to the far-ultraviolet circular dichroism of proteins. Eur Biophys J 1994;23:253-262.
72. Epand RF, Sayer BG, and Epand RM: The tryptophan-rich region of HIV gp41 and the promotion of cholesterol-rich domains. Biochemistry 2005;44:5525-5531.
73. Sreerama N and Woody RW: Estimation of protein secondary structure from circular dichroism spectra: Comparison of CONTIN, SELCON, and CDSSTR methods with an expanded reference set. Anal Biochem 2000;287:252-260.
74. Arrondo JLR and Goni FM: Structure and dynamics of membrane proteins as studied by infrared spectroscopy. Prog Biophys Mol Biol 1999;72:367-405.
75. Shu W, Liu J, Radigen L, Jiang S, and Lu M: Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides. Biochemistry 2000;39:1634-1642.
76. Chang D-K, Trivedi VD, Cheng S-F, and Francis S: The leucine zipper motif of the envelope glycoprotein ectodomain of human immunodeficiency virus type 1 contains conformationally flexible regions as revealed by NMR and circular dichroism studies in different media. J Peptide Res 2001;57:234-239.
77. Kliger Y and Shai Y: Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation. J Mol Biol 2000;295:163-168.
78. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, Ruker F, and Katinger H: A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993;67:6642-6647.
79. Parker CE, Deterding LJ, Hager-Braun C, Binley JM, Schulke N, Katinger H, Moore JP, and Tomer KB: Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing antibody 2F5. J Virol 2001;75:10906-10911.
80. 10-helix is formed in water by a 13-residue peptide representing the neutralizing determinant of HIV-1 on gp41. Biochemistry 2002;41:12687-12696.
81. Barbato G, Bianchi E, Ingallinella P, Hurni WH, Miller MD, Ciliberto G, Cortese R, Bazzo R, Shiver JW, and Pessi A: Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion. J Mol Biol 2003;330:1101-1115.
82. Ofek G, Tang M, Sambor A, Katinger H, Mascola JR, Wyatt R, and Kwong PD: Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol 2004;78:10724-10737.
83. Brasseur R, Cornet B, Burny A, Vandenbranden M, and Ruysschaert J-M: Mode of insertion into a lipid membrane of the N-terminal HIV gp41 peptide segment. AIDS Res Hum Retroviruses 1988;4:83-90.
84. Saez-Cirion A and Nieva JL: Conformational transitions of membrane-bound HIV-1 fusion peptide. Biochim Biophys Acta 2002;1564:57-65.
85. Fujii G, Horvath S, Woodward S, Eiserling F, and Eisenberg D: A molecular model for membrane fusion based on solution studies of an amphiphilic peptide from HIV gp41. Protein Sci 1992;1:1454-1464.
86. Veiga S, Henriques S, Santos NC, and Castanho M: Putative role of membrane in the HIV fusion inhibitor enfuvirtide mode of action at the molecular level. Biochem J 2004;377:107-110.
87. Furuta RA, Wild CT, Weng Y, and Weiss CD: Capture of an early fusion-active conformation of HIV-1 gp41. Nat Struct Biol 1998;5:276-279.
88. Qiao ZS, Kim M, Reinhold B, Montefiori D, Wang JH, and Reinheit EL: Design, expression and immunogenicity of a soluble HIV trimeric envelope fragment adopting a prefusion gp41 configuration. J Biol Chem 2005;280:23138-23146.
89. Neurath AR, Strick N, Lin K, and Jiang S: Multifaceted consequences of anti-gp41 monoclonal antibody 2F5 binding to HIV type 1 virions. AIDS Res Hum Retroviruses 1995;11:687-696.
90. Shu W, Ji H, and Lu M: Interactions between HIV-1 gp41 core and detergents and their implications for membrane fusion. J Biol Chem 2000;275:1839-1845.
91. Munoz-Barroso I, Salzwedel K, Hunter E, and Blumenthal R: Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion. J Virol 1999;73:6089-6092.
92. Aloia RC, Tian H, and Jensen FC: Lipid composition and fluidity of the human immunodeficiency virus envelope and host cell plasma membranes. Proc Natl Acad Sei USA 1993;90:5181-5185.
93. Vincent N, Genin C, and Malvoisin E: Identification of a conserved domain of the HIV-1 transmembrane protein gp41 which interacts with cholesteryl groups. Biochim Biophys Acta 2003;1567:157-164.
94. Rimsky LT, Shugars DC, and Matthews TJ: Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol 1998;72:986-993.
95. Fernandez A and Berry RS: Proteins with H-bond packing defects are highly interactive with lipids bilayers: Implications for amyloidogenesis. Proc Natl Acad Sci USA 2003;100:2391-2396.
96. Hildinger M, Dittmar MT, Schult-Dietrich P, Fehse B, Schnierle BS, Thaler S, Stiegler G, Welker R, and von Laer D: Membrane-anchored peptide inhibits human immunodeficiency virus entry. J Virol 2001;75:3038-3042.
97. Peisajovich SG, Gallo SA, Blumenthal R, and Shai Y: C-terminal octylation rescues an inactive T20 mutant. J Biol Chem 2003;278:21012-21017.
98. Egelhofer M, Brandenburg G, Martinius H, Schult-Dietrich P, Melikyan G, Kunert R, Baum C, Choi I, Alexandrov A, and von Laer D: Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J Virol 2004;78:568-575.
99. Gallaher WR, Ball JM, Garry RF, Griffin MC, and Montelaro RC: A general model for the transmembrane proteins of HIV and other retroviruses. AIDS Res Hum Retroviruses 1989;5:431-440.